Literature DB >> 17352237

Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro.

Gerhard Kelter1, Jörg M Schierholz, Imma U Fischer, Heinz-Herbert Fiebig.   

Abstract

Mistletoe extracts are widely used in complementary and alternative cancer therapy in Europe. The extracts possess cytotoxic, as well as immunostimulatory effects. However, some investigators have suggested that low doses of mistletoe extracts could also induce tumor growth. The mistletoe extracts Helixor A, Helixor M and Helixor P were investigated for growth inhibitory and stimulatory effects in a panel of 38 human tumor cell lines in vitro. Mistletoe lectin I (ML-1), adriamycin and interleukin-6 (IL-6) were used as reference compounds. All three mistletoe preparations showed cytotoxic activity [T/C (Test/Control) < 30%]: Helixor P was the most potent, followed by Helixor M and Helixor A with IC50 (50% inhibitory concentration) values of 68.4, 114 and 133 microg/ml, respectively. The IC50 values of ML-1 and adriamycin were 0.026 and 0.069 microg/ml. None of the human tumor cell lines in the panel showed growth stimulation (T/C (Test/Control) > 125%) by the mistletoe extracts or ML-1, apart from two exceptions in the colon carcinoma cell line HCC-2998, in which Helixor M and ML-1 showed a marginal stimulation (TIC 128% and 131%, respectively) at one concentration only. Further investigations into the latter effect of Helixor M and ML-1 in the HCC-2998 line using five different proliferation assays, modified cell culture conditions and the identical production charge of mistletoe extract, as well as a new one, did not confirm the previous observation. It was concluded that the marginal stimulation found in the earlier experiments was a statistical coincidence. Helixor mistletoe preparations and ML-1 have cytotoxic activity and do not stimulate tumor cell proliferation in vitro which is in accordance with previous scientifically based observations on aqueous mistletoe extracts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17352237

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Phytotherapy and Nutritional Supplements on Breast Cancer.

Authors:  C M Lopes; A Dourado; R Oliveira
Journal:  Biomed Res Int       Date:  2017-08-06       Impact factor: 3.411

2.  Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects.

Authors:  Roman Huber; Holger Lüdtke; Johannes Wieber; Christiane Beckmann
Journal:  BMC Complement Altern Med       Date:  2011-11-24       Impact factor: 3.659

Review 3.  Preclinical and clinical effects of mistletoe against breast cancer.

Authors:  Mohsen Marvibaigi; Eko Supriyanto; Neda Amini; Fadzilah Adibah Abdul Majid; Saravana Kumar Jaganathan
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

4.  Antioxidant Activity and ROS-Dependent Apoptotic Effect of Scurrula ferruginea (Jack) Danser Methanol Extract in Human Breast Cancer Cell MDA-MB-231.

Authors:  Mohsen Marvibaigi; Neda Amini; Eko Supriyanto; Fadzilah Adibah Abdul Majid; Saravana Kumar Jaganathan; Shajarahtunnur Jamil; Javad Hamzehalipour Almaki; Rozita Nasiri
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

5.  Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities.

Authors:  Michael Schink; Oliver Dehus
Journal:  BMC Complement Altern Med       Date:  2017-12-04       Impact factor: 3.659

6.  Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model.

Authors:  Carmen Steinborn; Amy Marisa Klemd; Ann-Sophie Sanchez-Campillo; Sophie Rieger; Marieke Scheffen; Barbara Sauer; Manuel Garcia-Käufer; Konrad Urech; Marie Follo; Annekathrin Ücker; Gunver Sophia Kienle; Roman Huber; Carsten Gründemann
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

7.  Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.

Authors:  Roman Huber; Dietrich Schlodder; Carola Effertz; Sabine Rieger; Wilfried Tröger
Journal:  BMC Complement Altern Med       Date:  2017-09-18       Impact factor: 3.659

Review 8.  Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research.

Authors:  Gunver S Kienle; Anja Glockmann; Michael Schink; Helmut Kiene
Journal:  J Exp Clin Cancer Res       Date:  2009-06-11

9.  Antiproliferative Activity of T. welwitschii Extract on Jurkat T Cells In Vitro.

Authors:  Batanai Moyo; Stanley Mukanganyama
Journal:  Biomed Res Int       Date:  2015-10-18       Impact factor: 3.411

10.  Insight into OroxylinA-7-O-β-d-Glucuronide-Enriched Oroxylum indicum Bark Extract in Oral Cancer HSC-3 Cell Apoptotic Mechanism: Role of Mitochondrial Microenvironment.

Authors:  Sharmila Kameyanda Poonacha; Madhyastha Harishkumar; Madhyastha Radha; Remya Varadarajan; Suchetha Kumari Nalilu; Shilpa Sharathraj Shetty; Praveen Kumar Shetty; Revanasiddappa Bistuvalli Chandrashekharappa; Mahendra Gowdru Sreenivas; Satheesh Kumar Bhandary Bavabeedu
Journal:  Molecules       Date:  2021-12-07       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.